Previous close | 1.7500 |
Open | 1.6000 |
Bid | 1.3000 |
Ask | 1.9500 |
Strike | 5.00 |
Expiry date | 2024-09-20 |
Day's range | 1.6000 - 1.6000 |
Contract range | N/A |
Volume | |
Open interest | 775 |
Tuesday, June 18, 2024 at 8:00 am Eastern TimePONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside
On May 14, 2024, Director Jane Kiernan purchased 19,356 shares of Treace Medical Concepts Inc (NASDAQ:TMCI), as reported in the SEC Filing.
On May 10, 2024, Deepti Jain, Director at Treace Medical Concepts Inc (NASDAQ:TMCI), purchased 25,000 shares of the company, as reported in a recent SEC Filing.